We are international
Donate
publications TEXT SIZE   



Newsletters


Summer 2014 Volume 14, Issue 3
Spring 2014 Volume 9, Issue 10
Winter 2013/2014 Volume 9, Issue 9
Fall 2013 Volume 9, Issue 8
Summer 2013 Volume 9, Issue 7
Spring 2013 Volume 9, Issue 6
Special Gala Report Volume 9, Issue 5
Winter 2012/2013 Volume 9, Issue 4
Fall 2012 Volume 9, Issue 3
Summer 2012 Volume 9, Issue 2
Spring 2012 Volume 9, Issue 1
MYELOMA TODAY – Special Gala Report Volume 8, Issue 11
Winter 2011 Volume 8, Issue 10
Fall 2011 Volume 8, Issue 9
Summer2011 Volume 8, Issue 8
Spring 2011 Volume 8, Issue 7
Special Gala Report Volume 8, Issue 6
Winter 2010 Volume 8, Issue 5
Fall 2010 Volume 8, Issue 4
Summer 2010 Volume 8, Issue 3
Spring 2010 Volume 8, Issue 2
Fall/Winter 2009/2010 Volume 8, Issue 1
Summer 2009 Volume 7, Issue 10
Spring 2009 Volume 7, Issue 9
Fall 2008 Volume 7, Issue 8
Summer 2008 Volume 7, Issue 7
Spring 2008 Volume 7, Issue 6
Winter 2008 Volume 7, Issue 5
Fall 2007 Volume 7, Issue 4
Summer 2007 Volume 7, Issue 3
Spring 2007 Volume 7, Issue 2
Winter 2006 Volume 7, Issue 1
Fall 2006 Volume 6, Issue 10
Summer 2006 Volume 6, Issue 9
Spring 2006 Volume 6, Issue 8
Winter 2005/2006 Volume 6, Issue 7
Fall 2005 Volume 6, Issue 6
Summer 2005 Volume 6, Issue 5
Spring 2005 Volume 6, Issue 4
Winter 2004/2005 Volume 6, Issue 3
Spring 2004 Volume 5, Issue 10
Winter 2003/2004 Volume 5, Issue 9
October 2003 Volume 5, Issue 8
August 2003 Volume 5, Issue 7
June 2003 Volume 5, Issue 6
February 2003 Volume 5, Issue 5
Winter 2002/2003 Volume 5, Issue 4
October 2002 Volume 5, Issue 3
August 2002 Volume 5, Issue 2
Special Edition - June 2002 Volume 4, Issue 11
April 2002 Volume 4, Issue 10
February 2002 Volume 4, Issue 9
Winter 2001/2002 Volume 4, Issue 8
Summer 1997 Volume 2, Issue 7

Summer 2014 Volume 14, Issue 3

Summer 2014 Volume 14, Number 3:
Myeloma Today Summer 2014
Volume 14 Number 3

Articles include:

  • Key Questions 2014: Highlights from the 5th Annual IMWG Summit
  • Highlights from the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO)
  • Living Well With Myeloma:  Expert Advice on Pain Management


Spring 2014 Volume 9, Issue 10

Myeloma Today Spring 2014
Volume 9 Number 10

Articles include:

  • SAR6500984:  A New "Blockbuster" Drug For Myeloma
  • Black Swan Research Initiative® (BSRI®) Debut of a Highly Sensitive MRD Test
  • Life is Good and Misery is Optional: A Conversation with Kenton Hofmeister


Winter 2013/2014 Volume 9, Issue 9

Myeloma Today Winter 2013/2014
Volume 9 Number 9

Articles include:

  • The 2013 Annual Meeting of the American Society of Hematolog y (ASH)
  • The International Myeloma Foundation (IMF) Black Swan Research Initiative® (BSRI®)
  • 7th Annual Comedy Celebration benefiting the Peter Boyle Research Fund


Fall 2013 Volume 9, Issue 8

Myeloma Today Fall 2013

Articles include:

  • IMWG Summit in Stockholm, Sweden
  • 11th Annual Robert M. Kyle Lifetime Achievement Awards
  • 14th Annual Myeloma Support Group Leaders Summit


Summer 2013 Volume 9, Issue 7

Myeloma Today Summer 2013

Articles include:

  • The Black Swan Research Initiative 
  • An interview with Dr. Kazuyuki Shimizu
  • The Nurse Leadership Board talks about New Paradigms in Multiple Myeloma Management


Spring 2013 Volume 9, Issue 6

Myeloma Today Spring 2013

Articles include:

  • The Nurse Leadership Board Talks about Subcutaneous Velcade® (bortezomib)
  • What is Pomalyst® (pomalidomide) and how is it used?
  • Cancer Coverage under the Affordable Care Act


Special Gala Report Volume 9, Issue 5

6th Annual Comedy Celebration benefiting the Peter Boyle Research Fund
Myeloma Today - Special Gala Report

On Saturday, October 27, 2012, nearly 1,200 guests gathered at the Wilshire Ebell Theatre in Los Angeles in support of the IMF’s 6th Annual Comedy Celebration. Save the date for this year's Comedy Celebration!


Winter 2012/2013 Volume 9, Issue 4

Myeloma Today Winter 2012/2013

Articles include:

  • Proteasome Inhibitors in Clinical Trials
  • Is there a recommended diet for cancer patients?
  • Strategies for Pain Management in Myeloma


Fall 2012 Volume 9, Issue 3

Myeloma Today Fall 2012

Articles include:

  • Update on New Drugs- Kyprolis™, Panobinostat and Pomalidomide
  • The New International Myeloma Working Group (IMWG) Master Class.
  • Report from the 2012 IMF Support Group Leaders’ Summit


Summer 2012 Volume 9, Issue 2

Myeloma Today Summer 2012

Articles include:

  • Report from ASCO 2012: New Results in Frontline and at Relapse
  • 10 Steps to Seeking a Second Opinion
  • Patient & Caregiver Experiences
  • Updates from Around the Globe


Spring 2012 Volume 9, Issue 1

Myeloma Today Spring 2012

Articles include:

  • Relapsed Multiple Myeloma After Therapy with IMiDs and Bortezomib
  • Survivorship Care Plan: Renal Complications in MM and Related Disorders
  • Updates from Asia


MYELOMA TODAY – Special Gala Report Volume 8, Issue 11

MYELOMA TODAY – Special Gala Report
on the 5th Annual Comedy Celebration benefiting the Peter Boyle Memorial Fund

A special edition packed with photos from the event. If you were there, or if you couldn't make it, you will want to see this.


Winter 2011 Volume 8, Issue 10

Myeloma Today Winter 2011

Articles include:

* Barbara Hammack: 20+ Years of Living with Myeloma
* Survivorship Care Plan: Maintaining Bone Health
* Dr. Morton Coleman Looks Back on His 45-Year Career in MM


Fall 2011 Volume 8, Issue 9

Myeloma Today Fall 2011

Articles include:

* The Role of Protein Electrophoresis Testing in Myeloma
* Survivorship Care Plan: Routine Health Maintenance for Patients Living with Multiple Myeloma
* The role of Mozobil® in Myeloma
* Prof. Douglas E. Joshua Receives the Robert A. Kyle Lifetime Achievement Award


Summer2011 Volume 8, Issue 8

Myeloma Today Summer 2011

Articles include:

* Current Role of Serum Free Light Chain Analysis in Myeloma
* Long-Term Survivorship Guidelines for Multiple Myeloma Patients
* Treating Spinal Fractures with Balloon Kyphoplasty
* Spotlight on Advocacy: A Day at the Capitol


Spring 2011 Volume 8, Issue 7

Myeloma Today Spring 2011

Articles include:

* ASH 2010 Summary of Multiple Myeloma Presentations
* Velcade® by Subcutaneous Injection
* IMF Hotline Coordinators Answer Your Questions: "My mother is 82 and fragile, and has been having trouble tolerating her myeloma treatments. Should we just give up on treatment altogether, or is there some way we can make the treatments more tolerable?"
* Spotlight on Advocacy: The IMF's 2011 Public Policy Agenda


Special Gala Report Volume 8, Issue 6

MYELOMA TODAY – Special Gala Report

4th Annual Comedy Celebration Benefiting the Peter Boyle Memorial Fund


Winter 2010 Volume 8, Issue 5

Myeloma Today Winter 2010

Articles include:

* Dr. Cristina Gasparetto talks about the current role of transplantation in myeloma
* The Hotline answers the question, "Does vitamin D deficiency play a role in myeloma?"
* Greg Pacini, a licensed counselor, talks about the difference between stress and stressors, suffering and pain, and the nature of discomfort.
* Robert Reeves biked 150 miles for charity a year following his diagnosis at 72!


Fall 2010 Volume 8, Issue 4

Myeloma Today Fall 2010 in PDF format

Articles include:

* The Role of Vorinostat in Relapsed/Refractory Multiple Myeloma
* The Role of Carfilzomib in Myeloma
* Multiple Myeloma and Sexual Dysfunction
* IMF Hotline Coordinators Answer Your Questions: "Is there a consensus among myeloma doctors on VELCADE dosing?"


Summer 2010 Volume 8, Issue 3

Myeloma Today Summer 2010

Articles include:

* Cure versus Control
* Induction Therapy Prior to Autologous Stem Cell Transplantation
* Mobility and Safety in the Multiple Myeloma Survivor
* Spotlight on Advocacy: Support Group Leaders fight for access to treatment – The Oral Drug Reimbursement Parity


Spring 2010 Volume 8, Issue 2

Myeloma Today Spring 2010

Articles include:

* Studies Presented at ASH 2009 May Offer New Approaches to Treating Myeloma
* Impact of Cytogenics on Overall and Event-Free Survival
* IMF Hotline Coordinators Answer Your Questions: "Is the use of gadolinium in MRI a necessary part of the imaging test and is it safe?"
* Spotlight on Advocacy: Important policies and political issues that impact the myeloma community


Fall/Winter 2009/2010 Volume 8, Issue 1

Myeloma Today Fall/Winter 2009/2010 + Special Gala Supplement

Articles include:

* Special Gala Report - IMF 3rd Annual Comedy Celebration
*Studies Presented at ASH 2009 May Offer New Approaches to Treating Myeloma
* 2010 IMF Research Grant Recipients Announced
* The Role of Freelite™ and Hevylite™ Serum Assays in Myeloma
* IMF Launches Major New Advocacy Initiative
* NLB Members Report on "Survivorship Care Plan" Progress
* ASH 2009 - A Patient's Perspective by Jack Aiello


Summer 2009 Volume 7, Issue 10

Myeloma Today Summer 2009

Articles include:

* Plerixafor and Transplantation in Myeloma
* Phase II Study of Carfilzomib in Patients with Relapsed Myeloma
* IMWG Studies Patients Who Have Exhausted Their Treatment Options
* 2009 Kyle Award Given to Prof. Jean-Luc Harousseau
* Dr. Brian G.M. Durie Honored for Lifetime of Achievement in Myeloma


Spring 2009 Volume 7, Issue 9

Myeloma Today Spring 2009 in PDF

Articles include:

* ASH 2008 Highlights for Patients
* 2009 IMF Research Grant Recipients Announced
* Korean Multiple Myeloma Working Party Comes Aboard IMWG
* Health Care Reform a Top Issue in 2009
* NLB members report from the XII International Myeloma Workshop
* MT in conversation with Prof. Roman Hajek, Chairman of the Czech Myeloma Group


Myeloma Today Spring 2009 in PDF

Articles include:

* ASH 2008 Highlights for Patients
* 2009 IMF Research Grant Recipients Announced
* Korean Multiple Myeloma Working Party Comes Aboard IMWG
* Health Care Reform a Top Issue in 2009
* NLB members report from the XII International Myeloma Workshop
* MT in conversation with Prof. Roman Hajek, Chairman of the Czech Myeloma Group


Fall 2008 Volume 7, Issue 8

Myeloma Today Fall 2008 in PDF

Articles include:

* The Role of Zolinza® in Multiple Myeloma
* Phase III Zolinza®/Velcade® Trial Opening Soon
* Serum Immunoglobulin Free Light Chain Assay in Myeloma
* Supportive Care: Steroid-Associated Side Effects in Patients with Myeloma
* Coping with Fear and Cancer Recurrence by John M. Ricco
* MT in conversation with IMF Board member Edith Peterson Mitchell, MD, FACP


Summer 2008 Volume 7, Issue 7

Myeloma Today Summer 2008 in PDF

Articles include:

* A Conversation with IMF Scientific Advisory Board Member Dr. Sagar Lonial
* Update from ASCO; MT in conversation with Dr. S. Vincent Rajkumar
* Supportive Care: Gastrointestinal side effects associated with myeloma therapies
* MT in conversation with Prof. Dr. Hermann Einsele
* MT in conversation with new IMF Board member Loraine Boyle


Spring 2008 Volume 7, Issue 6

Myeloma Today Spring 2008 in PDF

Articles include:

* A Conversation with IMF Scientific Advisory Board Member Dr. Alan Solomon
* Europe Update: Frontline Myeloma Therapy with Dr. Jesus San Miguel
* Curcumin in Multiple Myeloma with Dr. Bharat Aggarwal
* Clinical Trials Update with Dr. Keith Stewart


Winter 2008 Volume 7, Issue 5

Myeloma Today Winter 2007 in PDF

Articles include:

* New Findings Reported at ASH
* Serum Free Light Chain Testing for Diagnosis and Monitoring; MT in Conversation with Dr. Sundar Jagannath
* Myelosuppression; MT in conversation with Kathy Lilleby, RN


Fall 2007 Volume 7, Issue 4

Myeloma Today Fall 2007 in PDF

Articles include:

  • Patient & Caregiver Experience: Smoldering Battles: My Diagnosis with Smoldering Myeloma
  • Recommendations from the International Myeloma Working Group (IMWG): Prevention of blood clots associated with the use of thalidomide or lenalidomide
  • Peripheral Neuropathy; In Conversation with Ginger Love, RN


Summer 2007 Volume 7, Issue 3

Myeloma Today Summer 2007 in PDF format

Articles include:

  • Mapatumumab: A New Cancer Therapy in Development, with Dr. Asher A. Chanan-Khan
  • US Myeloma Forum, with Michael S. Katz
  • Thromboembolic Events, with Deborah Doss, RN, OCN


Spring 2007 Volume 7, Issue 2

Myeloma Today Spring 2007 in PDF format

Articles include:

  • The Role of VELCADE® plus DOXIL® in Multiple Myeloma; A Conversation with Dr. Robert Orlowski
  • Update on Revlimid® for the Treatment of Myeloma; A Conversation with Dr. S. Vincent Rajkumar
  • Health Care Becomes Key Issue in 110th Congress

Winter 2006 Volume 7, Issue 1

Winter 2006 Myeloma Today in PDF

Articles include:

  • Report from ASH 2006
  • Updates from around the globe
  • Patient profile: African Explorer and Seeker, Dr. William Wheeler Jr.


Fall 2006 Volume 6, Issue 10

Fall 2006 Myeloma Today in PDF

Articles include:

  • REVLIMID® Approved for Myeloma
  • Update from the Israeli Association of Myeloma Patients (AMEN)
  • Shifting Focus: My "New" Life with Multiple Myeloma


Summer 2006 Volume 6, Issue 9

Summer 2006 Myeloma Today in PDF

Articles include:

  • The 2006 IMF Scientific Board Retreat
  • The 2006 Annual Meeting of the American Society of Clinical Oncology
  • The IMF Symposium at the ONS Annual Congress: Advancing Access to Multiple Myeloma Treatmen


Spring 2006 Volume 6, Issue 8

Spring 2006 Myeloma Today in PDF

Articles include:

  • Focus on Myeloma and Plasma Cell Disorders; Conference Overview with Morton Coleman, MD
  • Update on the Role of Lenalidomide (Revlimid®) in Myeloma
  • The Role of Bortezomib in Previously Untreated Myelo


Winter 2005/2006 Volume 6, Issue 7

IMF's Centers for Disease Control and Prevention (CDC) grant renewed for second year

With our CDC grant renewal for 2006, the IMF will reach out to additional communities, as well as strengthen the community relationships we formed in 2005.


Advocacy Update: Support for Cancer Priorities Short-Changed in President’s Budget

President Bush’s recent state-of-the-union speech set the stage for an annual federal spending proposal that threatens to further erode our nation’s long-standing commitment to advance the pace of medical research and drug access.


The Yin and Yang of Long-Term Survivorship

Philosophers in the Han dynasty (207 BCE to 9 AD) developed the concept of Yin and Yang, the idea that everything in the universe has its opposite. If this is so, where does cancer fit into this ancient method of understanding life?


American Society of Hematology - 47th Annual Meeting

Recap from the American Society of Hematology's 47th annual meeting held in Atlanta, Georgia on December 10–14, 2005. We have selected the major myeloma presentations for you to keep informed on the latest myeloma research that was presented.


Dear Reader

2006! Another new year, one filled with new opportunities, new partnerships, and renewed hope. As is customary it's also a time to look back on what we've achieved and this year I'm especially proud of what the IMF has accomplished.


The Stafford Family Funds Myeloma Research Grant

To date, the four WAMP swim-a-thon events have raised more than $40,000—enough to fund a grant in my dad's honor through the IMF research program. Our family plans to continue our efforts to help fund myeloma research in hopes for a cure for my


Flavia Hiatt Shares Her Story

On August 13, 2005, Flavia and her friends transformed the boardroom and mezzanine of Luxe Hotel Rodeo Drive in Beverly Hills into a fabulous fashion trunk show to benefit the IMF's myeloma research program. Shop For A Cure featured Flavia's own clot


2006 IMF Brian D. Novis Research Grant Awards

Grant Recipients Honored at IMF Scientific Advisors Meeting.


Combination Therapy with VELCADE plus Melphalan & Prednisone

At the 2005 annual meeting of the American Society of Hematology, Dr. Jesús F. San Miguel presented interim data on the ongoing GEM/PETHEMA study of VELCADE® (bortezomib) plus melphalan and prednisone (V-MP) in elderly, previous


Pain Management in Multiple Myeloma

Myeloma Today speaks with Daniel R. Kloster, MD


Transplant Nutrition

Myeloma Today speaks with Heather-Ann Younker, RD, CNSD


My Life With Myeloma

It's important to know that you can lead a good life—and a long one—even with myeloma.


Board of Directors Profile: Matthew Robinson

This is a very exciting growth period for the Foundation. And it's enormously rewarding for me to apply my business experience of the last 20 years to helping the IMF accomplish its goals and objectives.


IMFers MAKE A DIFFERENCE!
2005 Member Fundraisers in Review

When the IMF started its member fundraising program several years ago, we had no idea how our members would respond. Would they be intimidated? After all, "fundraising" is a daunting word to some of us. Or would the opportunity of being pro


2005 Support Group Recap

As the IMF embarks on a new year, it serves well to look back at the accomplishments of 2005. It was an exciting year. Robin Tuohy, Kelly Cox, and I made visits to about a third of the myeloma support groups around the country. This was a very reward


The IMF Returns to St. Petersburg, Russia

International Clinical Conference Promotes Myeloma Education


IMF Hotline Coordinators Answer Your Questions

My brother was just told he has a very rare form of myeloma called IgM. I can’t find anything on it and keep coming across discussions of something called “Waldenström’s macroglobulinemia.” Can you help?


Fall 2005 Volume 6, Issue 6

Dear Reader

The IMF, along with researchers, physicians, patients, and industry leaders, is extremely excited as we prepare for the annual American Society of Hematology (ASH) meeting, this year being held in Atlanta, Georgia on December 10th through 13th. The I


Patient Perspectives: NUMBERS DON'T LIE, or do they?

In the business world we're often told that Figures Don't Lie, but that Liars Can Figure. While that may be true in some scandalous incidents of corporate wrongdoing, we who are cancer advocates also know that while medical statistics don't lie, that


IMF Around the Globe: Israeli Association of Myeloma Patients

The Israeli Association of Myeloma Patients, also known as AMEN, was founded to benefit the welfare of myeloma patients in Israel.


Sixth Annual Support Group Leader Retreat

The word "Retreat" is defined in various ways: (1) an act or process of withdrawing especially from what is difficult or dangerous, and also (2) a period of group withdrawal for meditation, study, and instruction under a director. Well, I would have


Making Clinical Trials More Patient-Friendly

All new cancer drugs must be proven safe and effective in clinical trials before they can be made available to patients. At the 2005 IMF Support Group Leader Retreat, IMFer and leader of the Manhattan and White Plains (New York) myeloma support group


Pathogenesis and Maintenance of Multiple Myeloma

Recent studies in my laboratory have identified a novel pathway promoting enhanced survival of chronic B cell malignancies. We demonstrated that B lymphocyte stimulator (BLyS), a member of the tumor necrosis factor family, was expressed in an autocri


MOZOBIL™, a potential new agent for Stem Cell Harvesting

Colony-stimulating factors such as G-CSF (filgrastim) induce the marrow to grow, while MOZOBIL is a new agent that aids in releasing stem cells into circulating blood where they can be collected by a process called apheresis.


Patient Experience: One Day at a Time...for 18 Years

The most powerful tool in a cancer patient's arsenal is the mind—when your body is beaten down physically, you can push your mind to keep you strong mentally while you face the challenges life has given you.


Education, Advocacy, and Awareness: Profile of Robin Tuohy

My family's journey through cancer began in September of 2000. My husband, Michael, and I were enjoying a family vacation with our children, Allison and Mikey, then ages 7 and 2. On one of the "kiddie" rides at Santa's Village, Michael experienced ex


IMF Hotline Coordinators Answer Your Questions

I have been diagnosed with a solitary plasmacytoma of the bone. What is it? And what is the likelihood that I will develop multiple myeloma?


The Multiple Myeloma ListServe

The Multiple Myeloma ListServ—affectionately called "The List" by its 1500 members—was founded by Michael Katz, an IMF Director, and June Brazil, a myeloma patient. At a time when the number of in-person myeloma support groups was nowhere


IMF Around the Globe: The Greater Montreal Multiple Myeloma Support Group

As The Greater Montreal Multiple Myeloma Support Group approaches its first anniversary, it is encouraging to review the progress that the group has made since our first meeting in November 2004.


Member Events: Gary C. Heuer, Jr. Memorial Golf Tournament

140 golfers started out the day’s activities with breakfast at Craigie Brae Golf Course in N. Chili, NY. Following the exciting 18-hole tournament, the event’s participants gathered for a chicken barbecue at Freeman Park in Mumford, NY.


Fundraising: Rocking in Rhode Island

Our mother, Carol Murray-Rossi, was diagnosed with multiple myeloma in 2003. But her personal struggle with this disease did not stop her from looking for ways to reach out and help others fighting myeloma.


Fundraising: Katie's Birthday Charity Bash

As Katie's birthday approached, she came to me with an idea of how she wanted to celebrate. In lieu of birthday gifts, Katie asked her friends to honor her grandmother by donating money to help cancer patients.


South Florida's Dynamic Duo: Cindy Feltzin and Vicki Anderson Ferraro

Every support group has a personality. Our group is a family. We want everyone who joins us to feel welcome, to feel safe, and to feel very hopeful.


IMF Board Member Interview with Benson and Carol Klein

Since being diagnosed, I have a different outlook. I used to worry about the little things. Now, I only think about the big picture.


Insights into New Myeloma Tx: Revlimid Study Tops List of Investigations that may Benefit Patients

Recently, the Myeloma Program at New York-Presbyterian Hospital/Weill Cornell Medical Center has generated a considerable amount of excitement by launching a study evaluating a combination regimen, known as BiRD, that includes the antibiotic Biaxin&r


Member Events: 4th Annual MMAMM Benefit Keeps Lee Grayson's Memory Alive

Lee, who never had children, or a hit song, or huge record deal, worried that his life would leave no mark on the planet. But those who knew him, and even those who never had the blessing of knowing him, feel his presence each year at MMAMM. "Ask any


Summer 2005 Volume 6, Issue 5

Education, Advocacy, and Awareness:
Chicago IMF Patient & Family Seminar

The seminar inspired me so much that starting a myeloma support group in my area is now one of my top priorities. With newly found hope, education, and knowledge of the IMF's passion for finding a cure, we feel more in control of our situation.


Education, Advocacy, and Awareness:
Cancer, Civil Rights, and Political Placebos

When truth meets politics to collaborate for change, great things can happen for future generations.


Meet the IMF: Allan Weinstein Joins the IMF Board of Directors

I was diagnosed around September of 2002. I had a symptom but it wasn’t a typical myeloma symptom. I was treated for an infection, but the infection recurred, and my internist didn’t like that.


The IMF Welcomes David Siegel, MD, PhD

The IMF is pleased to announce that Dr. David Siegel has joined its Scientific Advisory Board.


IMF Hotline Coordinators Answer Your Questions

My father-in-law has myeloma and may be a candidate for a stem cell transplant. I am pregnant. Can my baby’s umbilical cord blood be used for his transplant?


The International Myeloma Foundation’s CDC Initiative

The IMF is thrilled to have received a grant from the CDC to help in their efforts to increase awareness among African Americans regarding hematologic malignancies.


Revlimid® (Lenalinomide): Where Do We Stand?

One way or another, it seems that the long wait for Revlimid may be nearing an end.


IMF Honors Kenneth C. Anderson, MD with 2005 Robert A. Kyle Lifetime Achievement Award

Dr. Anderson has done more for the field of multiple myeloma and related disorders than anyone else. He is most deserving of this Lifetime Achievement Award.


IMF Around the Globe

The IMF in Japan and Latin America


Myeloma stem Cells: Attacking the Disease at its Source

Our research focuses on studying the originating cell in myeloma (the myeloma stem cell) and developing treatments that target this cell and inhibit the production of new tumor cells.


Dear Reader

I have just returned from a very successful meeting in Stockholm, Sweden, where exciting updates on myeloma research and treatments were presented.


Patient Perspective: Cancer Etiquette

The question most commonly asked of a patient is, “How are you?” There is inherently nothing wrong with such a question. But is it the standard “How are you?” we routinely ask when we aren’t really interested in the answer? Is it the mundane “How are


Patient Perspective: Tracking My Numbers

My MGUS was found as a fluke during an annual physical in May, 1993. My total serum protein was slightly above the top of the normal range for that test and soon went back to normal. Otherwise, I still would not know that I have MGUS since I am still


Update on Lenalidomide (CC-5013; Revlimid®)

There has been intense research to develop a safer and more effective version of thalidomide. Lenalidomide (CC-5013; Revlimid®) is the first analog (close cousin) of thalidomide to enter clinical trials. It may prove to be more effective and safe


Supportive Care: Erectile Dysfunction - Current Treatment Options

Erectile dysfunction (ED) is a very common disorder that affects up to half the male population over the age of 40.


IMF Hotline Coordinators Answer Your Questions

What is the difference between the terms "myeloma" and "multiple myeloma?" "My grandmother died of multiple myeloma and now my dad has been diagnosed with this disease. Is myeloma hereditary?"


Supportive Care: Blood Tests

There are a number of factors that are likely to increase your comfort with a medical test. Susan J. Leclair, PhD, CLS (NCA)helps you understand why a test has been ordered for you, how it will be conducted, and what the reference ranges are.


Community Goals Lead to Results

Are you more interested in myeloma research or cancer research? Is there a difference? What about other issues, like drug coverage and payments for PET scans? Can myeloma issues be separated from cancer issues in general?


Sorority Raises Funds for a Cure

During the summer of 2004, my father was diagnosed with multiple myeloma. Myeloma? I had never heard of this disease. And I was not alone.


Did You Know: What Causes Hyperviscosity in Multiple Myeloma?

Viscosity is the property of fluid to resist flow. In myeloma patients, hyperviscosity (increased serum viscosity) results from increased levels of circulating serum immunoglobulins.


Winter 2004/2005 Volume 6, Issue 3

Advocacy Update: Federal Support for Cancer Issues in Decline

The science of cancer research holds unprecedented promise. Unfortunately, the issues of federal funding dominating the political agenda—for cancer research and drugs and treatments through Medicare—are not addressing this opportunity.


Message from the IMF President

2004 saw the realization of many of the IMF’s dreams.


New Developments in Multiple Myeloma

Dr. Morie Gertz of the Mayo Clinic brings up to date on new developments in treatment and supportive care.


The Expanding Role of Proteasome Inhibition in Multiple Myeloma

At the 2004 ASH meeting, data from a variety of proteasome inhibitor studies was discussed. Based on these, it seems safe to conclude that more patients with relapsed or refractory disease will benefit from such therapy than previously thought.


IMFer Profile: Andy Lebkuecher
Meet the New IMF Director of Support Groups

Like most people who find out one day that they or a loved one has myeloma, we’d never heard of it before. I said, “OK, I guess we need to learn about this.”...We attended an IMF Patient & Family Seminar and became very involved with the Foundation.


Message from IMF President

On behalf of the International Myeloma Foundation, I would like to thank you for your support and update you on our progress with the IMF’s research project, Bank On A Cure®.


Why Bank On A Cure®?

Every myeloma patient is unique. Treatment should be too.


Treating Multiple Myeloma: The Little Rock Approach

Peripheral blood stem cell (PBSC)-supported high-dose melphalan 200 mg/m2 is now considered standard therapy for patients with symptomatic or progressive myeloma. During the last five years, additional new agents effecting salvage rates of 30% - 50%


The Genetics of Multiple Myeloma

Extensive genetic lesions, both at the chromosome and gene levels, characterize malignant plasma cells. Although most patients present with a large number of malignant plasma cells at diagnosis (up to 1,000 billion malignant cells), chromosomal analy


Drug Resistance: Overcoming Multiple Myeloma Drug Resistance by Inhibiting the Proteasome

There are many difficult hurdles to overcome in the treatment of multiple myeloma, but one of the most important is a phenomenon called drug resistance.


Education Initiative

The International Myeloma Foundation (IMF) and Millennium Pharmaceuticals, Inc., of Cambridge, MA, the developer of VELCADE® (bortezomib) for Injection, are collaborating on a national medical education program designed for oncology nurses.


Atiprimod: A New Drug Candidate in Early-Stage Development for Myeloma

Atiprimod has a very interesting history, providing yet another example of a drug candidate that begins its story as a potential treatment for a wholly different disease indication.


IMF Kicks Off 2004 Seminars with Florida Retreat

In talking with first-time participants as well as those who had attended IMF seminars previously, it is very evident that no matter how many of these wonderful weekends one has been to, there is always new, pertinent information available.


Winter 2003/2004 Volume 5, Issue 9 PDF AVAILABLE

2004 Research Grants Awarded to the Best
IMF Announces Key Worldwide Funding

Six of the world's most promising clinical investigators have been chosen to receive prestigious 2004 Brian D. Novis Research Grants from the International Myeloma Foundation (IMF) in order to further their research.


Message from IMF President

It’s that emotional time of year again, when we reflect back on the past year, sometimes with tears for what we’ve lost, sometimes with smiles for what we’ve achieved and for the sweet memories of people who have touched our lives.


Advocacy Update: Congress Adjourns

Thanks to the persistent work of Sen. Kay Bailey Hutchison (R-TX), the conferees to the Labor, Health and Human Services, and Education appropriations bill approved $500,000 to help support the IMF’s Bank On A Cure program.


October 2003 Volume 5, Issue 8 PDF AVAILABLE

Ask the Expert: The use of DOXIL® in multiple myeloma

An interview with Mohamad Hussein, M.D., Director of the Myeloma Research Program at the Cleveland Clinic Taussig Cancer Center in Cleveland, Ohio.


Myeloma at the Movies Lending Library

The IMF has set up a video lending library of a variety of presentations and question and answer sessions.


Saluting an Incredible Human Being:
Dr. Robert A. Kyle Receives Lifetime Achievement Award

Rochester, Minnesota is perhaps best known as the home of the Mayo Clinic. Most people to whom myeloma is not unknown also know that Rochester is home to Dr. Robert A. Kyle.


The IMF Visits Italy and France

Under the auspices of the IMF, IMF Scientific Advisors and distinguished Professors Mario Boccadoro and Jean-Luc Harousseau held the first ever IMF Patient & Family Seminars in their respective countries.


Myeloma Patients and Oncology Nurses to Benefit from IMF/Millennium Collaboration

The IMF and Millennium Pharmaceuticals have agreed to collaborate on a medical education initiative for oncology nurses nationally which will also benefit multiple myeloma patients in their care.


It’s Your Attitude... It’s Your Choice

Tom Bay, Ph.D. has asked audiences over and over again to answer the following questions: Whose life is it? Who’s responsible for it? What do you plan on doing about it? And last question… When?


Early studies indicate targeted radioactive drug may expand treatment options for myeloma

The studies involve the drug Quadramet, one of a new class of drugs that target radiation directly to bone and spare the rest of the body from exposure.


Veterans, Agent Orange, Multiple Myeloma, and VA Benefits

Veterans with MM who were exposed to Agent Orange (AO) are potentially eligible for a vast array of Department of Veterans Affairs (VA) benefits. NOTE: This article was updated on July 18, 2012.


August 2003 Volume 5, Issue 7 PDF AVAILABLE

Dear Reader


Ask the Expert:
The Pathogenesis and Treatment of Multiple Myeloma Bone Disease

One of the most common symptoms that lead patients with multiple myeloma to first seek medical attention is bone pain. This pain is caused by the destruction of bone material induced by myeloma cells within the center of the bone.


IMF Support Group Leader Retreat

Forty support group leaders, co-leaders, representatives, and IMF staff participated in the fourth annual IMF Support Group Leader Retreat, held June 27-29 at Duke University in Durham, North Carolina. The retreat lived up to the expectations of reg


The Good, the Bad, and the Ugly of Cancer Public Policy

On the one hand, the state of the science of cancer research and patient care is the brightest it has ever been. On the other hand, the politics and policy impacting the cancer world seem to be moving in the exact opposite direction.


IMFer Profile: Terry Herman Shares Her Story

I had an average life. I've always thought I was extremely healthy. I exercised, took all the right vitamins and antioxidants, and ate all the right foods. I used to laugh because my husband Howie was always running to the doctor, always thinking tha


Scientific Advisor Profile: Meet New Members of the IMF Scientific Advisory Board

The International Myeloma Foundation is pleased to welcome Drs. Fonseca, Gibson, Shimizu, and Westin to its distinguished Board of Scientific Advisors.


She's Banking on Finding a Cure

IMF President Susie Novis was profiled in the Leader's and Success section of the Investor's Business Daily.


June 2003 Volume 5, Issue 6 PDF AVAILABLE

Profile Interview: Julian Adams, Ph.D.

The doctor who discovered VelcadeTM, talks to Myeloma Today UK.


Dear Reader

For those not involved with Myeloma, the name Little Rock Arkansas evokes memories – good or bad – of President Clinton. For those of us who live in the Myeloma world, it means one thing: Dr. Bart Barlogie and his team at the center there.


Life Lessons from a Politician

In the rotunda of the Salt Lake City courthouse, a life-size bronze statue of Governor Scott Matheson comes striding out to meet you, its hand extended. It captures the energy Scott Matheson had in life. He was an extraordinary man.


Letters

At 53 years young, and at the pinnacle of my 25-year public relations career, I was struck by multiple myeloma....I took hold of myself and decided to go to any length to get healthy.


Myeloma Update

Overview of the IXth International Workshop on Multiple Myeloma, the International Prognostic Index, and Bank On A Curetm


Winter 2002/2003 Volume 5, Issue 4

Dear Reader

The beginning of a new year is always exciting. It’s a fresh start a clean slate — anything is possible. More than ever, I hear myeloma experts and researchers say that they believe we are on the brink of making myeloma a chronic disease. Can cure be


Ribbon of Hope — Making a World of Difference

As The Unknown Patient and his Unknown spouse dragged their luggage onto the shuttle to Washington DC, there was much to celebrate. His battle with myeloma was approaching its thirteenth year and for reasons far from Unknown, he was still going stron


Did You Know?
Immunizations in myeloma patients

Vaccination can help reduce the risk of some infections in individuals with multiple myeloma.


Did You Know?
The Gift of Good Nutrition

Almost everyone values the gift of health. By making small dietary changes you can reap rewards all year round.


Research Progress Report: Dr. Ivan Van Riet

A striking feature of myeloma cells concerns their tendency to reside in the bone marrow compartment during the main course of the disease evolution. The microenvironment provides the appropriate signals for growth and survival of the tumor cells. Si


Myeloma Center Spotlight: University of Arkansas for Medical Sciences

Comprehensive Molecular Management of Multiple Myeloma


August 2002 Volume 5, Issue 2 PDF AVAILABLE

IMF World Events


April 2002 Volume 4, Issue 10

Myeloma Today - April 2002

THE IMPORTANCE OF KNOWING POTENTIAL OUTCOME: Role for the new International Prognostic Index (IPI)[Now known as the International Staging System]


February 2002 Volume 4, Issue 9

Myeloma Today - February 2002


Thank You IMFers

It’s hard to believe that this year’s Ribbon of Hope-Making a World of Difference 11th Anniversary Gala has come and gone, raising close to $400,000!


Summer 1997 Volume 2, Issue 7

Mark Lenard: A Class Act

An Interview with Ann Lenard